Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report issued on Tuesday. The brokerage set a “buy” rating on the biotechnology company’s stock.

ADAP has been the subject of a number of other research reports. Jones Trading downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 11th. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research note on Friday, March 21st. Guggenheim decreased their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Scotiabank cut their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research note on Friday, March 21st. Finally, HC Wainwright decreased their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1.83.

Adaptimmune Therapeutics Price Performance

Shares of ADAP stock opened at $0.24 on Tuesday. The firm has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.57. The company has a market capitalization of $62.30 million, a PE ratio of -1.10 and a beta of 2.84. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.48. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Equities research analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in ADAP. Invesco Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP raised its position in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after buying an additional 58,787 shares in the last quarter. Two Sigma Investments LP lifted its stake in shares of Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares during the period. Virtu Financial LLC increased its stake in shares of Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 21,769 shares during the period. Finally, Jane Street Group LLC raised its holdings in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.